Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AB801 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Dose Escalation Cohort 1 - AB801 capsule Dose Level 1 | EXPERIMENTAL | Participants will receive AB801 orally daily |
| Dose Escalation Cohort 2 - AB801 capsule Dose Level 2 | EXPERIMENTAL | Participants will receive AB801 orally daily |
| Dose Escalation Cohort 3 - AB801 capsule Dose Level 3 | EXPERIMENTAL | Participants will receive AB801 orally daily |
| Dose Escalation Cohort 4 - AB801 capsule Dose Level 4 | EXPERIMENTAL | Participants will receive AB801 orally daily |
| Dose Escalation Cohort 5 - AB801 tablets Dose Level 5 | EXPERIMENTAL | Participants will receive AB801 orally daily |
| Dose Escalation Cohort 6 - AB801 tablets Dose Level 6 | EXPERIMENTAL | Participants will receive AB801 orally daily |
| Dose Escalation Cohort 7 - AB801 tablets Dose Level 7 | EXPERIMENTAL | Participants will receive AB801 orally daily |
| Dose Expansion Cohort - AB801 + Docetaxel | EXPERIMENTAL | Participants with NSCLC will receive AB801 orally in combination with docetaxel IV infusion |
| Cohort 1 - AB801 Dose A | EXPERIMENTAL | Participants will receive a single dose of AB801 or placebo |
| Cohort 2 - AB801 Dose B | EXPERIMENTAL | Participants will receive a single dose of AB801 or placebo |
| Cohort 3 - AB801 Dose C | EXPERIMENTAL | Participants will receive a single dose of AB801 or placebo |
| Cohort 4 - AB801 Dose D | EXPERIMENTAL | Participants will receive a single dose of AB801 or placebo |
| Name | Type | Description |
|---|---|---|
| AB801 | DRUG | Administered as specified in the treatment arm |
| Docetaxel | DRUG | Administered as specified in the treatment arm |
| Placebo | DRUG | Administered as specified in the treatment arm |
Key Inclusion Criteria: * Monotherapy-specific criteria for dose escalation cohorts: * Participants may have cytologically or pathologically confirmed non-small cell lung carcinoma (NSCLC), colorectal carcinoma (CRC), breast, ovarian, renal cell carcinoma (RCC), head and neck squamous cell carci...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
AB801 is an investigational small molecule being developed by Arcus Biosciences, Inc. for advanced cancer. It is designed to target the AXL protein and is currently in Phase 1 clinical development. It has been studied as both a monotherapy and in combination with other therapies in participants with advanced malignancies.
AB801 is being evaluated for the treatment of advanced cancer. It is an investigational therapy in Phase 1 development and has been studied in participants with advanced malignancies. It is not yet approved for any indication.
AB801 targets the AXL protein, a receptor tyrosine kinase. By inhibiting AXL, AB801 may interfere with signaling pathways that promote tumor growth and survival. This mechanism is being explored in advanced cancer.
AB801 is being developed by Arcus Biosciences, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol RCUS. The company is focused on developing therapies for cancer.
AB801 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any regulatory agency. The Phase 1 program includes studies in both healthy volunteers and participants with advanced cancer.
AB801 has been studied in two completed Phase 1 trials: NCT06120075, which evaluated AB801 monotherapy and combination therapy in participants with advanced malignancies, and NCT06004921, which assessed safety, pharmacokinetics, and pharmacodynamics in healthy volunteers. Both trials are listed as completed.